NASDAQ:ARAVAravive Stock Price, Forecast & News

Aravive's stock was trading at $4.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARAV shares have increased by 133.3% and is now trading at $11.64. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aravive.

Aravive is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Aravive.

Aravive Inc (NASDAQ:ARAV) announced its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.36. View Aravive's earnings history.

5 equities research analysts have issued 1-year target prices for Aravive's shares. Their forecasts range from $15.00 to $31.00. On average, they anticipate Aravive's stock price to reach $26.00 in the next year. This suggests a possible upside of 123.4% from the stock's current price. View analysts' price targets for Aravive.

Headlines about ARAV stock have trended negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aravive earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Aravive.

Aravive saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 264,400 shares, a decrease of 21.8% from the June 15th total of 338,000 shares. Based on an average daily volume of 157,500 shares, the short-interest ratio is presently 1.7 days. Approximately 3.0% of the shares of the company are short sold. View Aravive's Current Options Chain.

Some companies that are related to Aravive include Applied Therapeutics (APLT), Frequency Therapeutics (FREQ), ZIOPHARM Oncology (ZIOP), Homology Medicines (FIXX), Provention Bio (PRVB), Passage Bio (KROS), RAPT Therapeutics (RAPT), Eagle Pharmaceuticals (EGRX), VBI Vaccines (VBIV), Radius Health (RDUS), Trillium Therapeutics (TRIL), Cue Biopharma (CUE), Vanda Pharmaceuticals (VNDA), Atreca (BCEL) and Ardelyx (ARDX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Flexion Therapeutics (FLXN), Gilead Sciences (GILD), Applied Genetic Technologies (AGTC), Ardelyx (ARDX), Bank of America (BAC), Clovis Oncology (CLVS), Precision BioSciences (DTIL), Galmed Pharmaceuticals (GLMD), Inovio Pharmaceuticals (INO) and Myovant Sciences (MYOV).

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARAV stock can currently be purchased for approximately $11.64.

Aravive has a market capitalization of $186.24 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe.

The official website for Aravive is www.aravive.com.

Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]